Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN C BROWNING

Allopathic & Osteopathic Physicians Dermatology

NPI
1124181615
CMS profile
142316
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$16,155.84

102 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN C BROWNING

NPI 1124181615 · CMS profile ID 142316

Allopathic & Osteopathic Physicians / Dermatology

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124181615?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN C BROWNING, NPI 1124181615, CMS profile ID 142316. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124181615?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JOHN C BROWNING, NPI 1124181615, CMS profile ID 142316. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124181615?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JOHN C BROWNING, NPI 1124181615, CMS profile ID 142316, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 102 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1124181615?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

102 matching records · $16,155.84 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 102 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 102.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $121.1707/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809562469 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $14.7707/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849555897 CMS
Regeneron Healthcare Solutions, Inc. $11.6607/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809562467 CMS
LEO Pharma Inc. $11.4407/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842151207 CMS
AbbVie Inc. $0.6907/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794169019 CMS
Lilly USA, LLC $13.7107/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818570663 CMS
AbbVie Inc. $18.1707/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794169015 CMS
Janssen Biotech, Inc. $7.3007/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787876511 CMS
Novartis Pharmaceuticals Corporation $16.8606/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812620333 CMS
Lilly USA, LLC $14.9106/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818571441 CMS
PFIZER INC. $16.3406/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832502043 CMS
LEO Pharma Inc. $15.9706/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842151193 CMS
GENZYME CORPORATION $23.6406/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843609761 CMS
AbbVie Inc. $15.0206/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794169011 CMS
Janssen Biotech, Inc. $7.5006/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787876495 CMS
Regeneron Healthcare Solutions, Inc. $11.3106/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809562465 CMS
LEO Pharma Inc. $2.5606/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842151163 CMS
LEO Pharma Inc. $10.7406/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842151175 CMS
AbbVie Inc. $23.4206/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794169007 CMS
Genentech USA, Inc. $12.6805/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835927941 CMS
LEO Pharma Inc. $10.7705/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842151147 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $13.3205/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849555895 CMS
AbbVie Inc. $21.4205/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794169003 CMS
AbbVie Inc. $23.0805/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794168999 CMS
Lilly USA, LLC $8.6805/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819157323 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $14.8905/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851893333 CMS
GENZYME CORPORATION $16.3605/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843609735 CMS
LEO Pharma Inc. $14.5105/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842151129 CMS
Pierre Fabre Pharmaceuticals, Inc. $26.9504/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854637709 CMS
PFIZER INC. $8.2304/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833288561 CMS
Regeneron Healthcare Solutions, Inc. $18.4804/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809562463 CMS
AbbVie Inc. $28.5904/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794168995 CMS
Novartis Pharmaceuticals Corporation $480.0004/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812620325 CMS
Novartis Pharmaceuticals Corporation $11.8604/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812620327 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $18.3304/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851893335 CMS
LEO Pharma Inc. $13.0504/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842151111 CMS
Lilly USA, LLC $5.8004/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819157319 CMS
PFIZER INC. $17.2304/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832501353 CMS
Janssen Biotech, Inc. $16.3403/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787876527 CMS
AbbVie Inc. $19.0303/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794168991 CMS
PFIZER INC. $9.5603/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833288455 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $16.9503/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849555893 CMS
Novartis Pharmaceuticals Corporation $16.9703/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812620331 CMS
AbbVie Inc. $23.2903/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794168987 CMS
AbbVie Inc. $15.3302/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794168983 CMS
Janssen Biotech, Inc. $22.1902/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787876489 CMS
Regeneron Healthcare Solutions, Inc. $1,760.0002/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809562461 CMS
Kyowa Kirin, Inc. $17.9302/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852982653 CMS
AbbVie Inc. $24.8602/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794168979 CMS
GENZYME CORPORATION $22.6602/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843609719 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $39,531.74 116
PY2020 $15,102.85 45
PY2021 $16,155.84 102
PY2022 $42,401.04 151
PY2023 $45,175.70 206
PY2024 $97,494.83 249
PY2025 $94,916.22 246

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,160.14 7
PY2025 Principal investigator $2,082,447.74 329
PY2024 Recipient $12,422.58 3
PY2024 Principal investigator $1,724,395.97 752
PY2023 Recipient $5,832.00 1
PY2023 Principal investigator $1,177,285.76 612
PY2022 Recipient $8,234.10 5
PY2022 Principal investigator $692,813.32 90
PY2021 Recipient $6,272.50 7
PY2021 Principal investigator $1,053,264.90 82
PY2020 Recipient $1,123.60 3
PY2020 Principal investigator $1,431,344.77 107
PY2019 Recipient $18,929.61 8
PY2019 Principal investigator $2,232,845.85 131

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

336 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $1,665.00 12/25/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIAL
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175372692
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,476.25 12/24/2025 Non-covered Recipient Entity
Texas Dermatology and Laser Specialists
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435047
Principal investigator 1 SANOFI US SERVICES INC. $763.65 12/22/2025 Non-covered Recipient Entity
Texas Dermatology And Laser Special
A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants >=6 Months to <18 Years of Age With Prurigo Nodularis No dispute reported 06/30/2026 1226085853
Principal investigator 1 SANOFI US SERVICES INC. $15,073.00 12/22/2025 Non-covered Recipient Entity
Texas Dermatology And Laser Special
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226085855
Principal investigator 1 Galderma Laboratories, L.P. $2,000.00 12/19/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SP
A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1234517794
Principal investigator 1 Galderma Laboratories, L.P. $150.00 12/19/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SP
A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1234517797
Principal investigator 1 Galderma Laboratories, L.P. $3,554.92 12/19/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SP
A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1234517801
Principal investigator 1 Incyte Corporation $195.84 12/19/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598313
Principal investigator 1 Incyte Corporation $204.00 12/19/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598317
Principal investigator 1 Incyte Corporation $354.00 12/19/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598325
Principal investigator 1 Incyte Corporation $911.20 12/19/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598329
Principal investigator 1 Incyte Corporation $6,600.00 12/19/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598334
Principal investigator 1 Incyte Corporation $653.76 12/19/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598337
Principal investigator 1 Incyte Corporation $1,875.00 12/19/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598340
Principal investigator 1 Incyte Corporation $1,713.60 12/19/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598472
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $7,465.50 12/18/2025 Non-covered Recipient Entity
Texas Dermatology and Laser Specialists
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246435029
Principal investigator 1 PFIZER INC. $1,839.82 12/17/2025 Non-covered Recipient Entity
Texas Dermatology and Laser Specialists
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228733115
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $23,091.54 12/17/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SP
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289794
Principal investigator 1 Arcutis Biotherapeutics, Inc. $2,392.00 12/16/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis No dispute reported 06/30/2026 1248163814
Principal investigator 1 Incyte Corporation $6,789.60 12/11/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598310
Principal investigator 1 PFIZER INC. $4,614.29 12/11/2025 Non-covered Recipient Entity
Texas Dermatology and Laser Specialists
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228733807
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $31,510.92 12/10/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SP
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289498
Principal investigator 1 SANOFI US SERVICES INC. $5,206.50 12/08/2025 Non-covered Recipient Entity
Texas Dermatology And Laser Special
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226086003
Principal investigator 1 ABBVIE INC. $14,195.28 12/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202529094
Principal investigator 1 ABBVIE INC. $7,811.55 12/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202529096
Principal investigator 1 Incyte Corporation $9,061.50 12/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598303
Principal investigator 1 Incyte Corporation $14,068.20 12/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598306
Principal investigator 1 Incyte Corporation $1,037.70 12/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598320
Principal investigator 1 Incyte Corporation $10,727.70 12/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598465
Principal investigator 1 Incyte Corporation $4,897.80 12/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598469
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,646.11 12/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184269609
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $7,167.83 12/04/2025 Non-covered Recipient Entity
Texas Dermatology and Laser Specialists
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435043
Principal investigator 1 Janssen Research & Development, LLC $1,665.00 12/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIAL
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175372555
Principal investigator 1 Janssen Research & Development, LLC $6,217.00 12/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIAL
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175372656
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,370.96 12/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289089
Principal investigator 1 Eli Lilly and Company $11,221.00 11/25/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS No dispute reported 06/30/2026 1187891618
Principal investigator 1 Incyte Corporation $1,676.70 11/25/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598454
Principal investigator 1 PFIZER INC. $1,755.34 11/25/2025 Non-covered Recipient Entity
Texas Dermatology and Laser Specialists
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1228738729
Principal investigator 1 Incyte Corporation $1,713.60 11/20/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598457
Principal investigator 1 Janssen Research & Development, LLC $11,550.00 11/17/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIAL
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175372662
Principal investigator 1 SANOFI US SERVICES INC. $6,280.20 11/17/2025 Non-covered Recipient Entity
Texas Dermatology And Laser Special
A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants >=6 Months to <18 Years of Age With Prurigo Nodularis No dispute reported 06/30/2026 1226085995
Principal investigator 1 Incyte Corporation $936.90 11/14/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598299
Principal investigator 1 Incyte Corporation $1,676.70 11/14/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598461
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $6,508.35 11/13/2025 Non-covered Recipient Entity
Texas Dermatology and Laser Specialists
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246435018
Principal investigator 1 SANOFI US SERVICES INC. $31,355.00 11/10/2025 Non-covered Recipient Entity
Texas Dermatology And Laser Special
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226085999
Principal investigator 1 Incyte Corporation $2,008.80 11/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598293
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,403.86 11/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184258095
Principal investigator 1 ABBVIE INC. $13,446.84 11/05/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202521377
Principal investigator 1 ABBVIE INC. $5,098.95 11/05/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202521379
Principal investigator 1 Janssen Research & Development, LLC $3,724.00 11/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIAL
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175372530
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $33,488.46 11/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SP
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287871
Principal investigator 1 Janssen Research & Development, LLC $1,862.00 10/31/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIAL
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175372600
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $8,961.29 10/30/2025 Non-covered Recipient Entity
Texas Dermatology And Laser Specialists
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235993331
Principal investigator 1 Galderma Laboratories, L.P. $34.80 10/29/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SP
A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1234517353
Principal investigator 1 Incyte Corporation $1,676.70 10/29/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598445
Principal investigator 1 PFIZER INC. $20,986.38 10/29/2025 Non-covered Recipient Entity
Texas Dermatology and Laser Specialists
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RITLECITINIB IN PEDIATRIC PARTICIPANTS 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1228741525
Principal investigator 1 Janssen Research & Development, LLC $2,766.00 10/24/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIAL
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175372626
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,785.28 10/23/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184252878
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $10,416.60 10/23/2025 Non-covered Recipient Entity
Texas Dermatology and Laser Specialists
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246435021
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,616.98 10/23/2025 Non-covered Recipient Entity
Texas Dermatology and Laser Specialists
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246435025
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,547.98 10/22/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287311
Principal investigator 1 Eli Lilly and Company $49,924.00 10/21/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) No dispute reported 06/30/2026 1187890848
Principal investigator 1 Incyte Corporation $3,507.30 10/16/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598441
Principal investigator 1 Eli Lilly and Company $8,920.00 10/14/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187891270
Principal investigator 1 SANOFI US SERVICES INC. $3,951.00 10/14/2025 Non-covered Recipient Entity
Texas Dermatology And Laser Special
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226085982
Principal investigator 1 ABBVIE INC. $6,967.80 10/09/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202515799
Principal investigator 1 ABBVIE INC. $18,696.05 10/09/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202515801
Principal investigator 1 Incyte Corporation $2,854.80 10/09/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598289
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $9,709.20 10/09/2025 Non-covered Recipient Entity
Texas Dermatology and Laser Specialists
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246435011
Principal investigator 1 Incyte Corporation $3,394.80 10/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598284
Principal investigator 1 Incyte Corporation $4,814.10 10/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598450
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,064.03 10/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184244921
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $24,860.70 10/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SP
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286323
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,816.32 10/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286103
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,081.54 10/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223286145
Principal investigator 1 Janssen Research & Development, LLC $2,045.00 09/29/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIAL ISTS
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175372545
Principal investigator 1 Janssen Research & Development, LLC $1,665.00 09/29/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIAL ISTS
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175372702
Principal investigator 1 Galderma Laboratories, L.P. $480.00 09/24/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SP
A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1234516837
Principal investigator 1 PFIZER INC. $9,833.00 09/24/2025 Non-covered Recipient Entity
Texas Dermatology and Laser Specialists
A LONGTERM DOUBLEBLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031 No dispute reported 06/30/2026 1228757761
Principal investigator 1 Incyte Corporation $2,114.10 09/23/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598271
Principal investigator 1 Incyte Corporation $3,137.40 09/23/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598428
Principal investigator 1 SANOFI US SERVICES INC. $2,048.40 09/22/2025 Non-covered Recipient Entity
Texas Dermatology And Laser Special
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226085978
Principal investigator 1 Incyte Corporation $3,137.40 09/18/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598433
Principal investigator 1 Janssen Research & Development, LLC $10,239.00 09/16/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175284709
Principal investigator 1 Janssen Research & Development, LLC $500.00 09/16/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175284915
Principal investigator 1 Janssen Research & Development, LLC $6,368.00 09/16/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175285859
Principal investigator 1 SANOFI US SERVICES INC. $14,875.00 09/15/2025 Non-covered Recipient Entity
Texas Dermatology And Laser Special
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226085975
Principal investigator 1 Arcutis Biotherapeutics, Inc. $2,769.00 09/12/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis No dispute reported 06/30/2026 1248163812
Principal investigator 1 Incyte Corporation $4,383.00 09/12/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598275
Principal investigator 1 Incyte Corporation $4,814.10 09/12/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598437
Principal investigator 1 Janssen Research & Development, LLC $1,826.00 09/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIAL ISTS
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175372684
Principal investigator 1 ABBVIE INC. $10,706.40 09/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202509604
Principal investigator 1 ABBVIE INC. $11,029.25 09/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202509606
Principal investigator 1 Incyte Corporation $3,186.00 09/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598279
Principal investigator 1 Janssen Research & Development, LLC $6,447.00 09/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIAL ISTS
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175372561
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,474.08 09/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223284889
Principal investigator 1 Incyte Corporation $2,114.10 08/26/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598254
Principal investigator 1 Incyte Corporation $4,295.00 08/26/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598425
Principal investigator 1 Janssen Research & Development, LLC $2,513.00 08/25/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIAL ISTS
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175372609
Principal investigator 1 SANOFI US SERVICES INC. $2,048.40 08/25/2025 Non-covered Recipient Entity
Texas Dermatology And Laser Special
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226085971
Principal investigator 1 Incyte Corporation $1,071.90 08/21/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598258
Principal investigator 1 Incyte Corporation $4,608.00 08/21/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598421
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,432.47 08/21/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184229867
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $9,377.78 08/20/2025 Non-covered Recipient Entity
Texas Dermatology and Laser Specialists
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435040
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,233.96 08/19/2025 Non-covered Recipient Entity
Texas Dermatology and Laser Specialists
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246435005
Principal investigator 1 SANOFI US SERVICES INC. $15,245.00 08/18/2025 Non-covered Recipient Entity
Texas Dermatology And Laser Special
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226085962
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,469.32 08/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223284343
Principal investigator 1 Incyte Corporation $2,768.40 08/14/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598266
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,605.15 08/13/2025 Non-covered Recipient Entity
Texas Dermatology and Laser Specialists
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246435002
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $7,011.23 08/12/2025 Non-covered Recipient Entity
Texas Dermatology and Laser Specialists
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434996
Principal investigator 1 Incyte Corporation $2,523.60 08/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598262
Principal investigator 1 Incyte Corporation $2,941.20 08/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598417
Principal investigator 1 ABBVIE INC. $21,677.85 08/06/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202503461
Principal investigator 1 ABBVIE INC. $19,115.08 08/06/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202503567
Principal investigator 1 Janssen Research & Development, LLC $2,513.00 08/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIAL ISTS
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175372584
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,599.54 08/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283367
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,861.24 08/01/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283369
Principal investigator 1 Incyte Corporation $3,132.00 07/31/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598401
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $339.15 07/31/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184223040
Principal investigator 1 Janssen Research & Development, LLC $9,496.00 07/28/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIAL ISTS
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175372573
Principal investigator 1 Janssen Research & Development, LLC $2,201.00 07/28/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIAL ISTS
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175372589
Principal investigator 1 SANOFI US SERVICES INC. $4,802.40 07/28/2025 Non-covered Recipient Entity
Texas Dermatology And Laser Special
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226085958
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,755.00 07/23/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283012
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,800.00 07/23/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283014
Principal investigator 1 Incyte Corporation $3,680.10 07/22/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598397
Principal investigator 1 Eli Lilly and Company $5,244.56 07/17/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) No dispute reported 06/30/2026 1187890280
Principal investigator 1 Incyte Corporation $624.60 07/17/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598246
Principal investigator 1 Incyte Corporation $4,295.00 07/17/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598405
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $436.05 07/17/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184217358
Principal investigator 1 Galderma Laboratories, L.P. $6,495.50 07/16/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SP
A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1234515311
Principal investigator 1 SANOFI US SERVICES INC. $24,775.00 07/14/2025 Non-covered Recipient Entity
Texas Dermatology And Laser Special
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226085954
Principal investigator 1 Incyte Corporation $10,301.40 07/10/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598250
Principal investigator 1 Incyte Corporation $1,470.60 07/10/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598413
Principal investigator 1 PFIZER INC. $12,435.00 07/09/2025 Non-covered Recipient Entity
Texas Dermatology and Laser Specialists
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228771771
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,572.82 07/09/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223282456
Principal investigator 1 Incyte Corporation $1,830.60 07/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598409
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $726.75 07/04/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184213123
Principal investigator 1 ABBVIE INC. $8,811.00 07/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202496515
Principal investigator 1 ABBVIE INC. $2,689.35 07/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202496517
Principal investigator 1 SANOFI US SERVICES INC. $9,780.30 07/02/2025 Non-covered Recipient Entity
Texas Dermatology And Laser Special
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226085946
Principal investigator 1 SANOFI US SERVICES INC. $10,377.00 07/02/2025 Non-covered Recipient Entity
Texas Dermatology And Laser Special
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226085950
Principal investigator 1 Janssen Research & Development, LLC $9,534.00 06/26/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIAL ISTS
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175372567
Principal investigator 1 Incyte Corporation $3,102.30 06/24/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598232
Principal investigator 1 Novartis Pharmaceuticals Corporation $16,423.83 06/24/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1190307249
Principal investigator 1 Arcutis Biotherapeutics, Inc. $6,500.00 06/23/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis No dispute reported 06/30/2026 1248163810
Principal investigator 1 Incyte Corporation $15,053.40 06/19/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598237
Principal investigator 1 Incyte Corporation $3,661.20 06/19/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598387
Principal investigator 1 ABBVIE INC. $4,383.66 06/18/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) No dispute reported 06/30/2026 1202492127
Principal investigator 1 SANOFI US SERVICES INC. $23,633.00 06/16/2025 Non-covered Recipient Entity
Texas Dermatology And Laser Special
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226085932
Principal investigator 1 Incyte Corporation $643.50 06/12/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598392
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $20,167.32 06/06/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223280940
Principal investigator 1 Incyte Corporation $2,187.00 06/05/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598241
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.38 06/05/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184204455
Principal investigator 1 ABBVIE INC. $4,993.65 06/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202487839
Principal investigator 1 ABBVIE INC. $1,919.30 06/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202488027
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,299.88 05/30/2025 Non-covered Recipient Entity
Texas Dermatology and Laser Specialists
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435037
Principal investigator 1 Incyte Corporation $4,496.40 05/28/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598220
Principal investigator 1 Incyte Corporation $3,507.30 05/28/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598378
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,635.23 05/28/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184199103
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 05/28/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SP
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223280442
Principal investigator 1 Janssen Research & Development, LLC $9,398.00 05/26/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIAL ISTS
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175372633
Principal investigator 1 Janssen Research & Development, LLC $1,862.00 05/22/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIAL ISTS
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175372538
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,292.54 05/21/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223280068
Principal investigator 1 SANOFI US SERVICES INC. $5,729.00 05/19/2025 Non-covered Recipient Entity
Texas Dermatology And Laser Special
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226085938
Principal investigator 1 SANOFI US SERVICES INC. $26,076.00 05/19/2025 Non-covered Recipient Entity
Texas Dermatology And Laser Special
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226085943
Principal investigator 1 Incyte Corporation $2,333.70 05/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598228
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,530.52 05/13/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1190304339
Principal investigator 1 Incyte Corporation $2,456.10 05/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598225
Principal investigator 1 Incyte Corporation $1,676.70 05/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598382
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,409.24 05/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184193873
Principal investigator 1 ABBVIE INC. $22,522.50 05/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202483001
Principal investigator 1 ABBVIE INC. $2,589.17 05/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202483003
Principal investigator 1 PFIZER INC. $291.00 05/06/2025 Non-covered Recipient Entity
Texas Dermatology and Laser Specialists
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO No dispute reported 06/30/2026 1228781607
Principal investigator 1 SANOFI US SERVICES INC. $11,218.40 05/05/2025 Non-covered Recipient Entity
Texas Dermatology And Laser Special
An Open-Label Multinational, Multicenter Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1226085915
Principal investigator 1 Incyte Corporation $28,103.40 04/28/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598217
Principal investigator 1 Incyte Corporation $1,676.70 04/28/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598358
Principal investigator 1 Janssen Research & Development, LLC $2,310.00 04/28/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285278
Principal investigator 1 Janssen Research & Development, LLC $5,220.00 04/28/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIAL ISTS
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175372709
Principal investigator 1 SANOFI US SERVICES INC. $11,300.00 04/28/2025 Non-covered Recipient Entity
Texas Dermatology And Laser Special
A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants >=6 Months to <18 Years of Age With Prurigo Nodularis No dispute reported 06/30/2026 1226085927
Principal investigator 1 Eli Lilly and Company $4,994.13 04/23/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS No dispute reported 06/30/2026 1187890528
Principal investigator 1 Incyte Corporation $3,353.40 04/23/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598362
Principal investigator 1 Incyte Corporation $5,341.50 04/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598372
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,162.80 04/15/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184183234
Principal investigator 1 SANOFI US SERVICES INC. $6,490.00 04/14/2025 Non-covered Recipient Entity
Texas Dermatology And Laser Special
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226085920
Principal investigator 1 SANOFI US SERVICES INC. $8,539.60 04/14/2025 Non-covered Recipient Entity
Texas Dermatology And Laser Special
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226085922
Principal investigator 1 SANOFI US SERVICES INC. $3,175.80 04/14/2025 Non-covered Recipient Entity
Revival Research Institute, Inc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226126601
Principal investigator 1 SANOFI US SERVICES INC. $42.40 04/14/2025 Non-covered Recipient Entity
Revival Research Institute, Inc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226126605
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,648.20 04/11/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223278034
Principal investigator 1 Incyte Corporation $28,384.20 04/08/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598366
Principal investigator 1 ABBVIE INC. $2,116.40 04/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202472492
Principal investigator 1 ABBVIE INC. $12,559.95 04/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202473050
Principal investigator 1 SANOFI US SERVICES INC. $14,121.10 04/02/2025 Non-covered Recipient Entity
Texas Dermatology And Laser Special
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226085911
Principal investigator 1 Janssen Research & Development, LLC $7,733.00 03/27/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIAL ISTS
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175372618
Principal investigator 1 Janssen Research & Development, LLC $4,118.00 03/24/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIAL ISTS
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175372650
Principal investigator 1 SANOFI US SERVICES INC. $9,238.60 03/24/2025 Non-covered Recipient Entity
Texas Dermatology And Laser Special
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226085904
Principal investigator 1 SANOFI US SERVICES INC. $39,396.00 03/24/2025 Non-covered Recipient Entity
Texas Dermatology And Laser Special
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226085908
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $436.05 03/19/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184174322
Principal investigator 1 SANOFI US SERVICES INC. $3,000.00 03/17/2025 Non-covered Recipient Entity
Revival Research Institute, Inc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226126442
Principal investigator 1 SANOFI US SERVICES INC. $1,288.00 03/17/2025 Non-covered Recipient Entity
Revival Research Institute, Inc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226126446
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,112.48 03/11/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184170720
Principal investigator 1 Eli Lilly and Company $2,070.57 03/10/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1187890850
Principal investigator 1 SANOFI US SERVICES INC. $3,947.10 03/10/2025 Non-covered Recipient Entity
Texas Dermatology And Laser Special
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226085900
Principal investigator 1 ABBVIE INC. $13,694.85 03/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202460257
Principal investigator 1 ABBVIE INC. $4,232.80 03/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER
M17-380 - A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202460261
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,545.22 03/05/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223276029
Principal investigator 1 Janssen Research & Development, LLC $7,477.00 03/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIAL ISTS
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175372641
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,344.88 03/03/2025 Non-covered Recipient Entity
Texas Dermatology and Laser Specialists
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246435032
Principal investigator 1 Janssen Research & Development, LLC $3,466.00 02/27/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285739
Principal investigator 1 Janssen Research & Development, LLC $2,310.00 02/27/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285939
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,953.44 02/26/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223275647
Principal investigator 1 Eli Lilly and Company $1,072.78 02/25/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A PHASE 3, MULTICENTER, LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187890524
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $387.60 02/25/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184155574
Principal investigator 1 SANOFI US SERVICES INC. $27,556.10 02/24/2025 Non-covered Recipient Entity
Texas Dermatology And Laser Special
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226085888
Principal investigator 1 SANOFI US SERVICES INC. $13,375.00 02/24/2025 Non-covered Recipient Entity
Texas Dermatology And Laser Special
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226085897
Principal investigator 1 SANOFI US SERVICES INC. $22,906.60 02/24/2025 Non-covered Recipient Entity
Revival Research Institute, Inc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226126449
Recipient Regeneron Pharmaceuticals, Inc. $18.99 02/21/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184115905
Principal investigator 1 Janssen Research & Development, LLC $3,068.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284025
Principal investigator 1 Janssen Research & Development, LLC $1,974.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284033
Principal investigator 1 Janssen Research & Development, LLC $2,518.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284048
Principal investigator 1 Janssen Research & Development, LLC $156.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284077
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284088
Principal investigator 1 Janssen Research & Development, LLC $3,068.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284101
Principal investigator 1 Janssen Research & Development, LLC $1,974.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284106
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284139
Principal investigator 1 Janssen Research & Development, LLC $3,068.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284154
Principal investigator 1 Janssen Research & Development, LLC $156.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284177
Principal investigator 1 Janssen Research & Development, LLC $218.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284206
Principal investigator 1 Janssen Research & Development, LLC $218.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284241
Principal investigator 1 Janssen Research & Development, LLC $218.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284255
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284280
Principal investigator 1 Janssen Research & Development, LLC $2,518.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284346
Principal investigator 1 Janssen Research & Development, LLC $574.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284390
Principal investigator 1 Janssen Research & Development, LLC $3,068.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284408
Principal investigator 1 Janssen Research & Development, LLC $218.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284456
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284474
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284481
Principal investigator 1 Janssen Research & Development, LLC $1,974.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284499
Principal investigator 1 Janssen Research & Development, LLC $205.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284524
Principal investigator 1 Janssen Research & Development, LLC $574.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284532
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284582
Principal investigator 1 Janssen Research & Development, LLC $156.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284627
Principal investigator 1 Janssen Research & Development, LLC $574.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284660
Principal investigator 1 Janssen Research & Development, LLC $156.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284683
Principal investigator 1 Janssen Research & Development, LLC $205.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284704
Principal investigator 1 Janssen Research & Development, LLC $1,974.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284726
Principal investigator 1 Janssen Research & Development, LLC $6,500.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284780
Principal investigator 1 Janssen Research & Development, LLC $574.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284803
Principal investigator 1 Janssen Research & Development, LLC $1,974.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284818
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284843
Principal investigator 1 Janssen Research & Development, LLC $1,974.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284860
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284884
Principal investigator 1 Janssen Research & Development, LLC $218.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284890
Principal investigator 1 Janssen Research & Development, LLC $574.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284907
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175284988
Principal investigator 1 Janssen Research & Development, LLC $1,974.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285002
Principal investigator 1 Janssen Research & Development, LLC $218.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285018
Principal investigator 1 Janssen Research & Development, LLC $574.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285025
Principal investigator 1 Janssen Research & Development, LLC $218.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285034
Principal investigator 1 Janssen Research & Development, LLC $1,974.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285079
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285186
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285193
Principal investigator 1 Janssen Research & Development, LLC $218.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285215
Principal investigator 1 Janssen Research & Development, LLC $2,518.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285224
Principal investigator 1 Janssen Research & Development, LLC $205.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285270
Principal investigator 1 Janssen Research & Development, LLC $2,518.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285285
Principal investigator 1 Janssen Research & Development, LLC $1,974.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285309
Principal investigator 1 Janssen Research & Development, LLC $1,974.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285335
Principal investigator 1 Janssen Research & Development, LLC $205.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285342
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285348
Principal investigator 1 Janssen Research & Development, LLC $205.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285390
Principal investigator 1 Janssen Research & Development, LLC $218.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285397
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285422
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285450
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285494
Principal investigator 1 Janssen Research & Development, LLC $3,068.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285501
Principal investigator 1 Janssen Research & Development, LLC $3,068.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285584
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285652
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285709
Principal investigator 1 Janssen Research & Development, LLC $1,974.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285731
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285756
Principal investigator 1 Janssen Research & Development, LLC $218.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285800
Principal investigator 1 Janssen Research & Development, LLC $8,044.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285814
Principal investigator 1 Janssen Research & Development, LLC $156.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285849
Principal investigator 1 Janssen Research & Development, LLC $2,518.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285888
Principal investigator 1 Janssen Research & Development, LLC $205.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285894
Principal investigator 1 Janssen Research & Development, LLC $574.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285919
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285927
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285967
Principal investigator 1 Janssen Research & Development, LLC $156.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285974
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285981
Principal investigator 1 Janssen Research & Development, LLC $4,143.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285987
Principal investigator 1 Janssen Research & Development, LLC $2,518.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285993
Principal investigator 1 Janssen Research & Development, LLC $156.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175286003
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175286010
Principal investigator 1 Janssen Research & Development, LLC $2,500.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175286020
Principal investigator 1 Janssen Research & Development, LLC $156.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175286030
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175286036
Principal investigator 1 Janssen Research & Development, LLC $218.00 02/19/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175286044
Principal investigator 1 Novartis Pharmaceuticals Corporation $57.36 02/19/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
Pediatric Study in children with moderate to severe Plaque Psoriasis No dispute reported 06/30/2026 1190304341
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $724.88 02/18/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184154572
Principal investigator 1 SANOFI US SERVICES INC. $12,300.00 02/18/2025 Non-covered Recipient Entity
Texas Dermatology And Laser Special
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226085884
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,174.04 02/14/2025 Non-covered Recipient Entity
Texas Dermatology And Laser Specialists
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) No dispute reported 06/30/2026 1235993333
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,095.19 02/11/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184153136
Principal investigator 1 Janssen Research & Development, LLC $10,003.00 02/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIAL ISTS
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175372675
Recipient Regeneron Pharmaceuticals, Inc. $325.47 02/07/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184115895
Recipient Regeneron Pharmaceuticals, Inc. $68.89 02/07/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184115897
Recipient Regeneron Pharmaceuticals, Inc. $30.01 02/07/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184115899
Recipient Regeneron Pharmaceuticals, Inc. $96.17 02/07/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184115901
Recipient Regeneron Pharmaceuticals, Inc. $62.01 02/07/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184115903
Principal investigator 1 ABBVIE INC. $21,084.30 02/06/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202447215
Principal investigator 1 ABBVIE INC. $12,911.14 02/06/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER
M17-380 - A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202447219
Principal investigator 1 Incyte Corporation $624.60 02/05/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598355
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $23,649.06 02/05/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SP
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223274861
Principal investigator 1 SANOFI US SERVICES INC. $12,028.00 02/04/2025 Non-covered Recipient Entity
Texas Dermatology And Laser Special
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226085893
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,849.82 02/03/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223274685
Recipient Regeneron Pharmaceuticals, Inc. $558.60 01/31/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184115893
Principal investigator 1 Incyte Corporation $2,499.30 01/29/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598351
Principal investigator 1 Amgen Inc. $53,177.06 01/27/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246649181
Principal investigator 1 Eli Lilly and Company $942.96 01/27/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO ASSESS THE EFFICACY, SAFETY AND PHARMACOKINETICS OF LEBRIKIZUMAB COMPARED TO PLACEBO IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187892956
Principal investigator 1 Eli Lilly and Company $5,029.95 01/27/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187893106
Principal investigator 1 Janssen Research & Development, LLC $1,228.00 01/27/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175285563
Principal investigator 1 SANOFI US SERVICES INC. $1,180.00 01/27/2025 Non-covered Recipient Entity
Revival Research Institute, Inc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226126430
Principal investigator 1 SANOFI US SERVICES INC. $540.00 01/27/2025 Non-covered Recipient Entity
Revival Research Institute, Inc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226126434
Principal investigator 1 SANOFI US SERVICES INC. $4,000.00 01/27/2025 Non-covered Recipient Entity
Revival Research Institute, Inc
Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226126437
Principal investigator 1 Janssen Research & Development, LLC $2,451.00 01/24/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIAL ISTS
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175372595
Principal investigator 1 Eli Lilly and Company $62,695.00 01/22/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A PHASE 3, MULTICENTER, LONG-TERM EXTENSION STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187890466
Principal investigator 1 Eli Lilly and Company $10,928.00 01/22/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO ASSESS THE EFFICACY, SAFETY AND PHARMACOKINETICS OF LEBRIKIZUMAB COMPARED TO PLACEBO IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187892092
Principal investigator 1 Eli Lilly and Company $96,438.00 01/22/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187892094
Principal investigator 1 Incyte Corporation $1,561.50 01/17/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598344
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $484.50 01/17/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184148305
Principal investigator 1 Janssen Research & Development, LLC $12,084.00 01/16/2025 Non-covered Recipient Entity
Tx Derm and Laser Specialists
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175285117
Principal investigator 1 Eli Lilly and Company $104,731.90 01/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA No dispute reported 06/30/2026 1187890530
Principal investigator 1 Incyte Corporation $4,797.90 01/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240598348
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $920.55 01/07/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 1184146114
Principal investigator 1 ABBVIE INC. $420.00 01/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER
M17-380 - A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis (Start Up) No dispute reported 06/30/2026 1202433789
Principal investigator 1 Amgen Inc. $4,978.96 01/02/2025 Non-covered Recipient Entity
TEXAS DERMATOLOGY AND LASER SPECIALISTS
A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO) No dispute reported 06/30/2026 1246649186